-
DNA Damage Response (DDR) Inhibitors Pipeline Analytics, Deal Vales & Trends, 2024
Price range: $2,500.00 through $5,970.00 Select options This product has multiple variants. The options may be chosen on the product page -
Artificial Intelligence (AI) in Drug Development (Pharma & Biotech): Competition Analysis 2024
Price range: $3,500.00 through $7,000.00Select options This product has multiple variants. The options may be chosen on the product pageInnovation And Growth Dynamics: Analyzing Key Companies, Business Models, And Collaborative Ventures In Ai-enhanced Drug Development
- Strategic Analysis of AI-Driven Drug Discovery
- Geographical Impact on Biotech Innovations
- Top 10 Companies Business Models & Strategies’
- Mergers, Acquisitions, and Market Consolidation Trends
- Assessment of Clinical Pipeline Robustness
- Intellectual Property Strategy
- AI Technologies and Drug Development Efficiency
- Investment Recommendations Based on Current Trends
-
HER2-Low Gastric / Gastroesophageal Junction (GEJ) Adenocarcinoma | Primary Research (KOL’s Insight) | Market Intelligence | Epidemiology & Market Forecast-2034
Price range: $6,989.00 through $20,967.00Select options This product has multiple variants. The options may be chosen on the product pageAccording to Mellalta Meets Analyst’s most recent estimate, the HER2-Low Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma therapeutics market was worth US$ Billion in 2023 and is predicted to grow at a XX% CAGR to reach US$ Billion by 2034.
-
HER2-Low Breast Cancer– Pipeline Analytics 2023
Price range: $2,500.00 through $7,500.00Select options This product has multiple variants. The options may be chosen on the product pageThe 2023 Mellalta Meets report analyzes the HER2-Low Breast Cancer Therapies pipeline, highlighting the market opportunities and competitive landscape with over 30 companies developing pipeline drug profiles. The study marks a significant shift in breast cancer understanding, indicating over 50% of such cancers as HER2-low, thereby creating new prospects for therapeutic ADCs in treating HER2-low tumors. It also details the promising development pipeline involving a variety of ADCs and combination strategies to address this newly classified breast cancer subtype.
-
HER2-Low Metastatic Breast Cancer (mBC) | Primary Research (KOL’s Insight) | Market Intelligence | Epidemiology & Market Forecast-2034
Price range: $6,989.00 through $20,967.00Select options This product has multiple variants. The options may be chosen on the product pageAccording to Mellalta Meets Analyst’s most recent estimate, the HER2-Low Metastatic Breast Cancer therapeutics market was worth US$ Billion in 2023 and is predicted to grow at a XX% CAGR to reach US$ Billion by 2034.
-
Head and neck squamous cell carcinoma (HNSCC)| Primary Research (KOL’s Insight) | Market Intelligence | Epidemiology & Market Forecast-2033
Price range: $7,500.00 through $22,500.00Select options This product has multiple variants. The options may be chosen on the product pageAccording to Mellalta Meets Analyst’s most recent estimate, the Head and neck squamous cell carcinoma (HNSCC) therapeutics market for HNSCC s was worth US$ Billion in 2023 and is predicted to grow at a 13.9% CAGR to reach US$ 7.5 Billion by 2033.
-
Acute Myeloid Leukemia (AML) –KOLs Insight | Competitive Intelligence | Market Forecast 2033
Price range: $11,800.00 through $20,000.00
Price range: $5,900.00 through $10,000.00Select options This product has multiple variants. The options may be chosen on the product pageThe research study conducted by Mellalta Meets provides insights into the AML market dynamics, treatment trends, and key opportunities in the G7 regions. It highlights the need for novel targeted therapies, the potential of biomarker strategies, and the significant market opportunity for drug developers targeting the AML population. The study serves as a comprehensive resource for understanding the current landscape and future prospects of AML treatment.
-
Prader-Willi Syndrome (PWS)| Primary Research (KOL’s Insight) | Market Intelligence | Epidemiology & Market Forecast-2032
Price range: $6,989.00 through $20,967.00Select options This product has multiple variants. The options may be chosen on the product pageThe Prader-Willi Syndrome (PWS) market is hugely contributed by current standard of care (human growth hormone therapy) as there is no cure for PWS. By 2032, the market is expected to change due to the uptake and launch of new novel therapies. In a PWS treatment setting, the current SoC will decline, and the novel emerging drugs will grasp the highest market shares. The sales of the emerging therapies for the treatment of PWS in the study countries (United States, France, Germany, Italy, Spain, United Kingdom and Japan) will experience high growth over the 2018-2032 study period, adding a value estimated at a total market of $ 2.1 billion by 2032.
-
Peripheral T-cell lymphoma (PTCL)| Primary Research (KOL’s Insight) | Competitive Intelligence | Market Analytics & Forecast 2032
Price range: $6,989.00 through $20,967.00Select options This product has multiple variants. The options may be chosen on the product pageMellalta’s analysts estimate that the United States market is expected to show rapid growth, mainly attributed to, the launch of Adcetris in the front-line setting and expected approval of the potential therapies in the pipeline during the forecast period (2021-2030). Through this, the market size is set to show an extensive jump and grow at a CAGR of 15.3%
-
Pediatric Crohn’s Disease (pCD)| Primary Research (KOL’s Insight) | Market Intelligence | Epidemiology & Market Forecast-2032
Price range: $6,989.00 through $20,967.00Select options This product has multiple variants. The options may be chosen on the product pageDespite the availability of current therapeutics, there remains the unmet need for more effective treatment to reduce the recurrence rate which is quite high. Emerging drugs like Mirikizumab (Eli Lilly and Company), Stelara (Janssen Research & Development, LLC), Entyvio(Takeda Oncology), and others are likely capable to eliminate the current challenges and also have the potential to drive the market size of pediatric Crohn’s Disease (pCD). The reduced cost of biosimilars relative to Pediatric Crohn’s disease can drive market competition, contributing to budget sustainability and improving patient access to biologic treatments.
Call us today: +1 (304) 470-2225
English
You can use WPML or Polylang and their language switchers in this area.
Site License
Site License can be accessed by buyer’s team in a particular geographical area (eg USA region)
Home » Site License